Search research articles
Contact Us
Filters
Showing results (41-50 of 62) with videos related to
Page
of 7
Sort By:
Haematologica
|
June 22, 2023
Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia
Tracy Murphy, Jinfeng Zou, Andrea Arruda, et al.
Cancer Discovery
|
July 22, 2017
Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
Michael R McKeown, M Ryan Corces, Matthew L Eaton, et al.
The Lancet. Haematology
|
October 11, 2025
Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial
Guillaume Richard-Carpentier, Gopila Gupta, Charina Koraksic, et al.
Blood Advances
|
August 3, 2019
Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML
Tracy Murphy, Jinfeng Zou, Georgina S Daher-Reyes, et al.
British Journal of Haematology
|
December 4, 2025
Real-world experience with CPX-351 for secondary acute myeloid leukaemia: Comparison with FLAG-IDA in a propensity score matching analysis
Maria Agustina Perusini, Ana Flavia Patiño, Claire Andrews, et al.
Leukemia
|
March 2, 2024
Asparaginase completion among adults including older patients with acute lymphoblastic leukemia treated with a modified DFCI protocol
Maria Agustina Perusini, Claire Andrews, Atenafu G Eshetu, et al.
Blood Neoplasia
|
January 23, 2026
Single-cell proteogenomic analysis of clonal evolution in PDX models of AML treated with IDH inhibitors
Alex C H Liu, Severine Cathelin, Dhanoop Manikoth Ayyathan, et al.
Leukemia
|
December 19, 2023
Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms
Tracy Murphy, Jacqueline M Mason, Brian Leber, et al.
Science Translational Medicine
|
April 10, 2020
The mitochondrial peptidase, neurolysin, regulates respiratory chain supercomplex formation and is necessary for AML viability
Sara Mirali, Aaron Botham, Veronique Voisin, et al.
Oncotarget
|
November 3, 2016
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes
Polina Matre, Juliana Velez, Rodrigo Jacamo, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 62) with videos related to
Sort By:
Page
of 7
Haematologica
|
June 22, 2023
Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia
Tracy Murphy, Jinfeng Zou, Andrea Arruda, et al.
Cancer Discovery
|
July 22, 2017
Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
Michael R McKeown, M Ryan Corces, Matthew L Eaton, et al.
The Lancet. Haematology
|
October 11, 2025
Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial
Guillaume Richard-Carpentier, Gopila Gupta, Charina Koraksic, et al.
Blood Advances
|
August 3, 2019
Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML
Tracy Murphy, Jinfeng Zou, Georgina S Daher-Reyes, et al.
British Journal of Haematology
|
December 4, 2025
Real-world experience with CPX-351 for secondary acute myeloid leukaemia: Comparison with FLAG-IDA in a propensity score matching analysis
Maria Agustina Perusini, Ana Flavia Patiño, Claire Andrews, et al.
Leukemia
|
March 2, 2024
Asparaginase completion among adults including older patients with acute lymphoblastic leukemia treated with a modified DFCI protocol
Maria Agustina Perusini, Claire Andrews, Atenafu G Eshetu, et al.
Blood Neoplasia
|
January 23, 2026
Single-cell proteogenomic analysis of clonal evolution in PDX models of AML treated with IDH inhibitors
Alex C H Liu, Severine Cathelin, Dhanoop Manikoth Ayyathan, et al.
Leukemia
|
December 19, 2023
Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms
Tracy Murphy, Jacqueline M Mason, Brian Leber, et al.
Science Translational Medicine
|
April 10, 2020
The mitochondrial peptidase, neurolysin, regulates respiratory chain supercomplex formation and is necessary for AML viability
Sara Mirali, Aaron Botham, Veronique Voisin, et al.
Oncotarget
|
November 3, 2016
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes
Polina Matre, Juliana Velez, Rodrigo Jacamo, et al.
Page
of 7